Ab-vcMMAE

Ab-vcMMAE refers to an antibody-drug conjugate (ADC) platform or benchmark construct consisting of a monoclonal antibody (Ab) conjugated to the microtubule inhibitor monomethyl auristatin E (MMAE) through a cathepsin-cleavable valine-citrulline (vc) linker. This specific configuration is one of the most widely utilized ADC technologies, characterized by a stable linker in systemic circulation that releases the potent cytotoxic payload upon internalization into the lysosomal compartment of target cells. In the context of preclinical oncology research, "Ab-vcMMAE" is often employed as a reference or benchmark molecule to compare the anti-tumor activity of novel antibodies or alternative payload classes (such as Topoisomerase I inhibitors) against a standard-of-care ADC architecture. In specific studies, such as those conducted by Biocytogen, it is used as a benchmark targeting Cadherin-3 (CDH3) to evaluate the relative potency of new therapeutic candidates.